Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil in lupus glomerulonephritis.

Chi Chiu Mok1, Kar Neng Lai

  • 1Department of Medicine, Tuen Mun Hospital, New Territories, Hong Kong. cmok@netvigator.com

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|August 30, 2002
PubMed
Summary

Mycophenolate mofetil (MMF) shows promise for lupus nephritis, offering an effective alternative to cyclophosphamide (CYC) with fewer toxicities. Further research is needed to confirm long-term efficacy and establish its role in treatment protocols.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

C5a/C5aR1 mediates AKI-CKD transition by enhancing autophagy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Vaccination in systemic lupus erythematosus.

Human vaccines & immunotherapeutics·2026
Same author

Herpes zoster vaccination and flares in rheumatic diseases.

The Lancet. Rheumatology·2026
Same author

How the Cigarette Fire Burns the Rheumatoid Joints.

JMA journal·2025
Same author

EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update.

Annals of the rheumatic diseases·2025
Same author

Lupus nephritis.

Nature reviews. Disease primers·2025

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Optimal treatment for severe lupus nephritis remains uncertain.
  • Current standard, cyclophosphamide (CYC), has limitations including treatment resistance, progression to end-stage renal disease, and significant toxicities.
  • There is a need for more effective and less toxic therapeutic options.

Purpose of the Study:

  • To evaluate the efficacy and safety of mycophenolate mofetil (MMF) as a treatment for lupus nephritis.
  • To compare MMF with existing therapies, particularly CYC.

Main Methods:

  • Review of existing data on MMF in solid-organ transplantation and experimental models of lupus nephritis.
  • Analysis of preliminary uncontrolled and small controlled studies of MMF in lupus nephritis patients.

Related Experiment Videos

Main Results:

  • MMF selectively inhibits activated lymphocytes and renal mesangial cells.
  • Experimental data suggest MMF ameliorates autoimmune phenomena and retards renal damage.
  • Uncontrolled studies indicate MMF efficacy in patients refractory to conventional agents.
  • Small controlled studies show MMF is comparable to CYC for short-term renal remission.
  • MMF appears well-tolerated with significantly less ovarian toxicity than CYC.

Conclusions:

  • MMF demonstrates potential as an effective and safer alternative for lupus nephritis treatment.
  • Its reduced toxicity profile is particularly advantageous for patients of reproductive age.
  • Further long-term efficacy data and comparative studies are required to establish MMF as a first-line therapy.